Available at research and GMP grade to intensify production of recombinant AAV rAAV viral vectors at any scale from benchtop to 2000L scale bioreactor...
Watch this webinar to understand how DoE can have a direct impact on process development for the complex manufacturing projects in AAV gene therapy applications and Finding capable partners with the requisite expertise to optimize AAV processes using DoE can be important in reducing variability and risk
Our experts form Andelyn and Polyplus will discuss key considerations for taking your advanced therapy from concept to commercialization with confidence.
Key Learning Objectives:
- AAV Manufacturing Platforms
- Optimization by Design
- Benefits of the DoE Approach including selected case studies